Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines the oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumor types Myricx Bio’s first-in-class NMTi payload platform is designed to improve the therapeutic […]
Financing led by leading life sciences venture capital firm Forbion, with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington’s disease Forbion General Partner Rogier Rooswinkel joins Board of Directors […]
Tuning in to the field of targeted cancer medicine through molecular radiotherapy or targeted radionuclides.
This is a fantastic initiative that helps young businesses by providing the support they need to succeed. This includes up to USD 500,000 in fundraising, introduction to a dynamic network and access to free lab space.
